Anacor Pharmaceuticals Inc (ANAC) Monday announced that its partner GlaxoSmithKline (GSK) has voluntarily paused enrollment in its current clinical trials of GSK2251052.
Anacor further stated that GSK had recently identified microbiological finding in a small number of patients in the Phase 2b trial of GSK '052 for the treatment of complicated urinary tract infections.
GSK is in the process of obtaining additional information in order to better understand the data, but will not resume the trials until it has concluded its investigation. Upon completion of the review, GSK will determine next steps regarding the future development of GSK '052.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org